2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Pathogenesis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

1842 Safety and efficacy of duvelisib in relapsed/refractory peripheral T-cell lymphoma: A real-world multicenter analysis

Priyanka Pullarkat, MD, Kishan Patel, MD2, Marcus Watkins, PhD3, Tiffany Chang4, Nivetha Ganesan, MPH5, Katie Ksanznak6, Alison Moskowitz, MD7, Omar Elghawy, MD8, Stefan K Barta, MD9, Youssef Youssef, MD10, Jonathan Brammer, MD11, Katelin Baird12, Darina Paulino13, Pamela Allen, MD14, Josie Ford15, Salvia Jain, MD16, Sirui Ma17, Mwanasha Merrill, MD18, Shambhavi Singh, MD, PhD19, Jie Wang, MD MS20, Lauren Shea, MD21, Mahsa Ahadi22, Adrienne N. Nedved, PharmD, MPA23, Nora Bennani, MD24, Fatima Tuz Zahra25, Yumeng Zhang, MD26, Neha Akkad, MD27, Swaminathan P. Iyer, MD28, Alexander D. Sanjurjo, B.S.29, Seda S. Tolu, MD30, Evelyn Hastings Orlando, MD31, Jia Ruan, MD, PhD32, Bret Wankel, MD33, Danielle Wallace, MD34, Conner Liddle35, Harsh Rohit Shah, DO36, Joe Lukowski, MPH37, Nic Weber38, Matthew A. Lunning, DO, FACP39, Matthew Sawaged40, Bradley Haverkos, MD41, Neha Mehta-Shah, MD, MSCI42
1 Washington University in St. Louis, St. Louis, Missouri, United States
2 Memorial Sloan Kettering, New York City, United States
3 Washington University in St. Louis, St. Louis, Missouri, United States
4 Memorial Sloan Kettering, New York City, United States
5 Memorial Sloan Kettering, New York City, United States
6 Memorial Sloan Kettering, New York City, United States
7 Memorial Sloan Kettering, New York City, United States
8 Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 Hospital of The University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 Ohio State University, Columbus, Ohio, United States
11 Ohio State University, Columbus, Ohio, United States
12 Emory University, Atlanta, Georgia, United States
13 Emory University, Atlanta, Georgia, United States
14 Emory University, Atlanta, Georgia, United States
15 Massachusetts General Hospital, Boston, Massachusetts, United States
16 Massachusetts General Hospital, Boston, Massachusetts, United States
17 University of California San Francisco, San Francisco, California, United States
18 University of California San Francisco, San Francisco, California, United States
19 Duke University, Durham, North Carolina, United States
20 Duke University, Durham, North Carolina, United States
21 University of Alabama at Birmingham, Birmingham, Alabama, United States
22 Mayo Clinic College of Medicine & Science, Rochester, Minnesota, United States
23 Mayo Clinic College of Medicine & Science, Rochester, Minnesota, United States
24 Mayo Clinic College of Medicine & Science, Rochester, Minnesota, United States
25 Moffitt Cancer Center, Tampa, Florida, United States
26 Moffitt Cancer Center, Tampa, Florida, United States
27 MD Anderson Cancer Center, Houston, Texas, United States
28 MD Anderson Cancer Center, Houston, Texas, United States
29 Columbia University Vagelos College of Physicians & Surgeons, New York, New York, United States
30 Columbia University Irving Medical Center, New York, New York, United States
31 Weill Cornell Medicine, New York, New York, United States
32 Weill Cornell Medicine, New York, New York, United States
33 University of Rochester, Rochester, New York, United States
34 UR Medicine Wilmot Cancer Institute - White Spruce Boulevard, Rochester, New York, United States
35 University of Utah Huntsman Center, Salt Lake City, Utah, United States
36 University of Utah Huntsman Center, Salt Lake City, Utah, United States
37 University of Nebraska, Lincoln, Nebraska, United States
38 University of Nebraska, Lincoln, Nebraska, United States
39 University of Nebraska, Lincoln, Nebraska, United States
40 Creighton University School of Medicine, Omaha, Nebraska, United States
41 The University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
42 Washington University in St. Louis, St. Louis, Missouri, United States

Background: Relapsed/refractory (R/R) peripheral T-cell lymphomas (PTCL) have poor prognosis and limited treatment options; median survival is 6-10 months (mo). Duvelisib is an oral ϒ/∆ phosphatidylinositol 3-kinase inhibitor that has been shown to be safe and effective in R/R PTCL and is NCCN-listed (Mehta-Shah, JCO 2026). In indolent lymphomas, concerns about cumulative toxicity have limited its use. We sought to evaluate the safety and efficacy of duvelisib in R/R PTCL in a real-world cohort.

Methods: We conducted a retrospective analysis of patients (pts) with R/R PTCL treated with duvelisib as a single agent or in combination therapy at 18 US centers from 2012-2025.

Results: 328 pts were identified including: nodal PTCL with TFH phenotype (n=166, 51%); PTCL-NOS (n=117, 36%); ALCL (n=24, 7%), EATL (n=8, 2%); ATLL (n=7, 2%), hepatosplenic TCL (n=4, 1%); and ENKTL (n=2, 0.6%). 139 pts were female (42%). The median age of diagnosis was 63 (range 14-89) and median International Prognostic Index score 3 (range 1-5). Median prior lines of therapy was 2 (range 1-9). 12 pts received duvelisib maintenance after autologous stem cell transplant and were excluded from our efficacy analysis.

Of the efficacy cohort, 177 pts received duvelisib alone and 139 pts received duvelisib with other therapies (romidepsin [n=109], bortezomib [n=11], CHOP [n=2], Gem-Ox [n=2], ruxolitinib [n=8], oral azacitadine [n=4], and other regimens [n=3]).

Overall response rate (ORR) was 46% (145/316; CR 32%; PR 14%). ORR in pts with TFH-phenotype vs. non-TFH phenotype was 58% (94/161; CR 46%, PR 12%) and 33% (51/155; CR 17%, PR 15%) respectively (p<0.001). ORR was 41% (72/177; CR 27%, PR 14%) in single agent and 53% (73/139; CR 38%, PR 14%) in combination therapy (p=0.05). Median overall survival (OS) was 10 mo (10 mo single agent, 11 mo combination, p=0.45). Median OS for TFH vs. non-TFH phenotype was 16 mo vs 8 mo (p= 0.055). Median progression free survival (PFS) for the full cohort was 5 mo (4 mo single agent, 6 mo combination, p=0.054). Median PFS for TFH vs. non-TFH phenotype was 8 mo vs. 2 mo (p=0.003).

Median duration of therapy was 76 days. 84% (267/316) discontinued duvelisib therapy, most often for disease progression (57%, 151/267). In 109 pts who had duration of response (DOR) data available, the median DOR was 250 days (range 6-3638 days). 16% (51/316) underwent allogeneic transplant after duvelisib therapy.

88% (289/328) of pts experienced toxicity related to duvelisib. The most common non-infectious toxicities were cytopenias (55%, 180/328), transaminitis (41%, 134/328), rash (16%, 51/328), colitis (11%, 37/328) and pneumonitis (3%, 10/328). Toxicity rates were similar between pts receiving duvelisib alone vs in combination with the exceptions of cytopenias (74% [106/144] combination vs. 40% [74/184] single-agent, p< 0.001), and colitis, (7% [10/144] combination vs. 15% [27/184] single-agent, p= 0.051).

Of pts who had laboratory values available, grade ≥3 hematologic toxicities included thrombocytopenia (24%, 73/303), anemia (23%, 69/300), and neutropenia (11%, 34/296). Grade ≥3 ALT and/or AST elevation each occurred in 13% (37/296). Duvelisib treatment holds occurred in 39% (129/328); duvelisib was restarted in 49% (63/129) of these pts with a median treatment hold of 14 days. 19% (61/328) experienced at least one unplanned dose reduction, most often due to transaminitis (30%, 18/61), cytopenias (26%, 16/61) and colitis (15%, 9/61). 16% (52/328) discontinued duvelisib due to organ toxicity (22 transaminitis, 19 colitis, 6 cytopenia, 5 pneumonitis).

Hospitalization (H) or steroids (S) were required for pneumonitis (n=10; 60% H, 70% S); colitis (n=37, 62% H, 78% S); rash (n=51, 14% H, 55% S). 130 pts had data available on transaminitis management (10% H, 15% S). Infections occurred in 32% (106/328); 68% of whom required hospitalization. 6% discontinued duvelisib due to infection. The most common infections were bacteremia (24%), COVID-19 (18%), pneumonia (14%), and fungal infections (11%).

Conclusion: In this real-world, multicenter analysis of 328 R/R PTCL pts treated with duvelisib-based regimens, the ORR was 46%. ORR of 58% in TFH phenotype was consistent with the recently published PRIMO study. Toxicity was manageable with higher rates of cytopenias in pts treated with combination regimens and higher rates of colitis in single agent. Our findings demonstrate duvelisib is a safe and efficacious therapy in R/R PTCL. 

Priyanka Pullarkat, MD: No relevant conflicts of interest to declare.